Merck SG&A Expenses 2010-2024 | MRK
Merck annual/quarterly sg&a expenses history and growth rate from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Merck sg&a expenses for the quarter ending March 31, 2024 were $2.483B, a 0.16% increase year-over-year.
- Merck sg&a expenses for the twelve months ending March 31, 2024 were $10.508B, a 3.04% increase year-over-year.
- Merck annual sg&a expenses for 2023 were $10.504B, a 4.6% increase from 2022.
- Merck annual sg&a expenses for 2022 were $10.042B, a 4.24% increase from 2021.
- Merck annual sg&a expenses for 2021 were $9.634B, a 7.58% increase from 2020.
Merck Annual SG&A Expenses
(Millions of US $) |
| 2023 |
$10,504 |
| 2022 |
$10,042 |
| 2021 |
$9,634 |
| 2020 |
$8,955 |
| 2019 |
$9,455 |
| 2018 |
$10,102 |
| 2017 |
$10,074 |
| 2016 |
$10,017 |
| 2015 |
$10,313 |
| 2014 |
$11,606 |
| 2013 |
$11,911 |
| 2012 |
$12,776 |
| 2011 |
$13,733 |
| 2010 |
$13,125 |
| 2009 |
$8,543 |
Merck Quarterly SG&A Expenses
(Millions of US $) |
| 2024-03-31 |
$2,483 |
| 2023-12-31 |
$2,804 |
| 2023-09-30 |
$2,519 |
| 2023-06-30 |
$2,702 |
| 2023-03-31 |
$2,479 |
| 2022-12-31 |
$2,687 |
| 2022-09-30 |
$2,520 |
| 2022-06-30 |
$2,512 |
| 2022-03-31 |
$2,323 |
| 2021-12-31 |
$2,830 |
| 2021-09-30 |
$2,336 |
| 2021-06-30 |
$2,281 |
| 2021-03-31 |
$2,187 |
| 2020-12-31 |
$2,255 |
| 2020-09-30 |
$2,060 |
| 2020-06-30 |
$2,085 |
| 2020-03-31 |
$2,555 |
| 2019-12-31 |
$1,729 |
| 2019-09-30 |
$2,589 |
| 2019-06-30 |
$2,712 |
| 2019-03-31 |
$2,425 |
| 2018-12-31 |
$2,643 |
| 2018-09-30 |
$2,443 |
| 2018-06-30 |
$2,508 |
| 2018-03-31 |
$2,508 |
| 2017-12-31 |
$2,643 |
| 2017-09-30 |
$2,459 |
| 2017-06-30 |
$2,500 |
| 2017-03-31 |
$2,472 |
| 2016-12-31 |
$2,848 |
| 2016-09-30 |
$2,393 |
| 2016-06-30 |
$2,458 |
| 2016-03-31 |
$2,318 |
| 2015-12-31 |
$2,616 |
| 2015-09-30 |
$2,472 |
| 2015-06-30 |
$2,624 |
| 2015-03-31 |
$2,601 |
| 2014-12-31 |
$2,924 |
| 2014-09-30 |
$2,975 |
| 2014-06-30 |
$2,973 |
| 2014-03-31 |
$2,734 |
| 2013-12-31 |
$2,981 |
| 2013-09-30 |
$2,803 |
| 2013-06-30 |
$3,140 |
| 2013-03-31 |
$2,987 |
| 2012-12-31 |
$3,390 |
| 2012-09-30 |
$3,063 |
| 2012-06-30 |
$3,249 |
| 2012-03-31 |
$3,074 |
| 2011-12-31 |
$3,704 |
| 2011-09-30 |
$3,340 |
| 2011-06-30 |
$3,525 |
| 2011-03-31 |
$3,164 |
| 2010-12-31 |
$3,536 |
| 2010-09-30 |
$3,192 |
| 2010-06-30 |
$3,175 |
| 2010-03-31 |
$3,222 |
| 2009-12-31 |
$3,455 |
| 2009-09-30 |
$1,726 |
| 2009-06-30 |
$1,730 |
| 2009-03-31 |
$1,633 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$327.467B |
$60.115B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
